Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited Sponsored ADR (RADX)
NASDAQ:RADX
RADX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.08 - $50.82
Previous CloseN/A
Volume12.21K
Average Volume (3M)51.90K
Market Cap
$32.84M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.47
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.28
Shares Outstanding7,779,934
10 Day Avg. Volume41,604
30 Day Avg. Volume51,895
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Radiopharm Theranostics Limited Sponsored ADR News
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
5.58% Other Institutional Investors
94.42% Public Companies and
Individual Investors
RADX FAQ
What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?
Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $3.08 and its highest was $50.82 in the past 12 months.
What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?
Radiopharm Theranostics Limited Sponsored ADR’s market cap is $32.84M.
When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?
Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Sep 25, 2025 which is in 154 days.
How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?
Radiopharm Theranostics Limited Sponsored ADR released its earnings results on Feb 28, 2025. The company reported -$1.912 earnings per share for the quarter, beating the consensus estimate of -$1.969 by $0.057.
Is Radiopharm Theranostics Limited Sponsored ADR overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Overvalued.
Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?
Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.
What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?
Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?
Radiopharm Theranostics Limited Sponsored ADR has 7,779,934 shares outstanding.
What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?
Radiopharm Theranostics Limited Sponsored ADR reported an EPS of -$1.912 in its last earnings report, beating expectations of -$1.969. Following the earnings report the stock price went down -2.153%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?
Currently, no hedge funds are holding shares in RADX
---
Radiopharm Theranostics Limited Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-111.73%
Trailing 12-Months
Asset Growth
32.54%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
---
RADX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Atara Biotherapeutics
―
NRX Pharmaceuticals
―
Reviva Pharmaceuticals Holdings
―
LakeShore Biopharma
―
RenovoRx
―
Best Analysts Covering RADX
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-22.80%
initiated a buy rating last month
Copying Yuan Zhi's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -22.80% per trade.
---